Login
$STAA
$26.01 -$0.38 (1.44%) Live

$STAA SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
04 Nov 2026 10-Q
04 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Adjusted EBITDA[1]of $14.4 Million, or $0.28 per Diluted Share

27 Oct 2026 SCHEDULE 13G/A
05 Oct 2026 8-K/A: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

The architect of STAAR's global refractive transformation returns to lead STAAR's next commercial chapter as EVO ICL outpaces a declining laser refractive market

10 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

The architect of STAAR's global refractive transformation returns to lead STAAR's next commercial chapter as EVO ICL outpaces a declining laser refractive market

18 Aug 2026 Form 4: Foust Warren, President and CEO

Received 10,997 shares by exercise or conversion · Gave up 5,595 shares to cover exercise price or tax ($146K) · Granted 22,493 Restricted Stock Units · 3 more

18 Aug 2026 Form 4: Andrews Deborah J, Chief Financial Officer & EVP

Received 5,233 shares by exercise or conversion · Gave up 2,662 shares to cover exercise price or tax ($69.7K) · Granted 4,975 Restricted Stock Units · 3 more

18 Aug 2026 Form 4: Michna Magda, Chief Development Officer

Received 6,599 shares by exercise or conversion · Gave up 3,356 shares to cover exercise price or tax ($87.9K) · Acquired 6,599 Performance Stock Units (Option Exercise/Conversion)

14 Aug 2026 SCHEDULE 13G/A
12 Aug 2026 10-Q
12 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Adjusted EBITDA1 of $20.0 million, or $0.39 per diluted share

06 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

STAAR Surgical Company, a Delaware corporation, (the “Company”), pursuant to its Amended and Restated Omnibus Equity Incentive Plan, as may be amended from time to time (the “Plan”), hereby grants to the individual listed below (“Partici...

04 Aug 2026 Form 4: Foust Warren, President and CEO

Received 20,787 shares by exercise or conversion · Gave up 10,576 shares to cover exercise price or tax ($258K)

04 Aug 2026 Form 4: Andrews Deborah J, Chief Financial Officer & EVP

Received 13,955 shares by exercise or conversion · Gave up 6,480 shares to cover exercise price or tax ($202K) · Received 20,787 shares by exercise or conversion · 1 more

24 Jun 2026 S-8
23 Jun 2026 Form 4: Wang Christopher Min Fang, Director

Granted 11,145 Common Stock Option

22 Jun 2026 Form 4: LeBuhn Richard T., Director

Granted 11,145 OPTION TO PURCHASE COMMON STOCK

22 Jun 2026 Form 4: Bradsher Neal C, Director

Granted 11,145 OPTION TO PURCHASE COMMON STOCK

22 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

This Amendment No. 2 (the “Amendment No. 2”) to the STAAR Surgical Company Amended and Restated Omnibus Equity Incentive Plan (the “Plan”) is adopted by the Board of Directors (“Board”) of STAAR Surgical Company, a Delaware corporation (...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support